(Reuters) - ZURICH, July 27 - Swiss drugmaker Novartis said on Friday it would make its bowel drug Zelnorm available to U.S. patients on a restricted basis after pulling the product from the market at the request of regulators.
Novartis said it has established a restricted access programme for Zelnorm in cooperation with U.S. regulators.
Read more at Reuters.com Government Filings News
Novartis said it has established a restricted access programme for Zelnorm in cooperation with U.S. regulators.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment